AstraZeneca: A Vision for a Collaborative Clinical Environment

Slides from AstraZeneca's 2019 Veeva R&D Summit presentation.

After receiving the 2018 Eagle Award for the best sponsor by the Society for Clinical Research Sites (SCRS), AstraZeneca is on an ongoing quest to remain a sponsor of choice for 2019 and beyond. Learn how they are leveraging technology, a unified clinical trial platform, and other strategies to simplify trial conduct at sites.

1. A Vision for a Collaborative Clinical Environment
Doug Schantz, Executive Director, Development Operations
Veeva R&D Summit 9 September 2019

2. More Trials Drive More Competition for Sites
2000 2004 20192008 2012 2016
# of Trials
0
300,000
250,000
200,000
150,000
100,000
50,000
# of Trials Linear (# of Trials)
Differentiation
isimportant

3. 3
Opportunity to Become the Sponsor of Choice
`31%
CRA & sponsor
relationship
Scientific value
of research
24%
Quality of trial
documents
11%
Site training
9%
Important factors for study coordinators

4. 2016 2017 2018 2019
and beyond
AstraZeneca’s Road to Sponsor of Choice
4
OPERATING MODEL FOCUS
TECHNOLOGY TRANSFORMATION

5. Strategies to be the Sponsor of Choice:
Operating Model
5
In-sourced model leverages improved site relationships to be
“sponsor of choice” and decrease non-enrolling sites
Invest in site development, outreach, and collaboration
Build a site customer service model
Build an in-house function

6. 6
CONGRATULATIONS TO THE 2018 EAGLE AWARD WINNERS

7. Strategies to be the Sponsor of Choice:
Technology Transformation
7
Shift IT strategy to
information sharing
Understand your
customer & provide
standardized
technology
Invest in unified
clinical platform

8. Strategies to be the Sponsor of Choice:
Technology Transformation
8
Shift IT strategy to
information sharing
Understand your
customer & provide
standardized
technology
Invest in unified
clinical platform

9. Drive Value with Unified Clinical Platform:
AstraZeneca Perspective
9
Manual MVR preparation Automation and speed $10M
Disparate site health data Unified and consistent $4M
Manual investigator & site
activation doc distribution
Repeatable user experience $3M
Value Metrics*Unified Clinical BenefitsChallenges
*These are projected cost reduction estimates

10. Strategies to be the Sponsor of Choice:
Technology Transformation
10
Understand your
customer & provide
standardized
technology
Invest in unified
clinical platform
Shift IT strategy to
information sharing

11. Technology Realities
11
SCRS Summit Survey 2016, CenterWatch 2016
CenterWatch
19%
25%
34%
37%
39%
46%
60%
74%
Too many usernames /
passwords
Repetitive training
Too many different
technologies
Too much training
Slow system response time
Incompatible tech
Lack of tech support
Tech too complex to use
SCRS
13%
16%
16%
17%
20%
Too many systems
Repetitive training
Too many usernames /
passwords
Systems not aligned with
site workflow
Insufficient tech support

12. Technology Enabler: Site Business Processes
12
Site
Sponsor #1
Technology supports
site operations and
workflows
Sponsor
#1 Trial
Sponsor
#2 Trial
Sponsor
#3 Trial
CRO #1
Trial
CRO #2
Trial
Sites can standardize
on technology and use
across all studies
1
2

13. Drive Value with Unified Clinical Platform:
Site Perspective
13
Time to start a study Repeatable user experience Site activation cycle time
Budgetsand payments Automation, consistency, speed Site satisfaction, engagement
Complexity of systems Simplified user experience Site satisfaction, training time
MetricsUnified Clinical BenefitsChallenges

14. Shift IT strategy to
information sharing
Strategies to be the Sponsor of Choice:
Technology Transformation
14
Invest in unified
clinical platform
Understand your
customer & provide
standardized
technology

15. Shift IT Strategy to Information Sharing
15
Site
Site
Site
Sponsor
CRO

16. 16
Think Differently.
31%
CRA & sponsor
relationship
Scientific value
of research
24%
Quality of trial
documents
11%
Site training
9%
Important factors for study coordinators
Invest in unified
clinical platform
Understand your
customer & provide
standardized
technology
Shift IT strategy to
information sharing

17. Confidentiality Notice
This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove
it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use ordisclosure of the
contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus,
Cambridge, CB2 0AA, UK, T: [phone], www.astrazeneca.com
17